Abstract
Radiofrequency (RF) ablation has gained great popularity in the treatment of Hepatocellular Carcinoma (HCC) on cirrhosis and is replacing Percutaneous Ethanol Injection (PEI) in treating 3cm or less HCC nodules. Its necrotic effect is more predictable than that of PEI and therefore RF can achieve a longer local tumor progression control and survival. In the last four years many data on its efficacy have been added in the Literature and long-term results on 3-5-year survival are available. In this review article data of the last 4 years on percutaneous RF ablation of HCC on cirrhosis are discussed in order to give an answer to questions put forward on this matter at 2000 EASL Barcelona Consensus Conference. Moreover, new perspectives in the percutaneous treatment of some form of advanced HCC (the so-called percutaneous thrombectomy) are presented together with some patents in the treatment of HCC.
Keywords: Cirrhosis, hepatocellular carcinoma, radiofrequency ablation, percutaneous interventional ultrasound
Recent Patents on Anti-Cancer Drug Discovery
Title: Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives
Volume: 5 Issue: 1
Author(s): Antonio Giorgio
Affiliation:
Keywords: Cirrhosis, hepatocellular carcinoma, radiofrequency ablation, percutaneous interventional ultrasound
Abstract: Radiofrequency (RF) ablation has gained great popularity in the treatment of Hepatocellular Carcinoma (HCC) on cirrhosis and is replacing Percutaneous Ethanol Injection (PEI) in treating 3cm or less HCC nodules. Its necrotic effect is more predictable than that of PEI and therefore RF can achieve a longer local tumor progression control and survival. In the last four years many data on its efficacy have been added in the Literature and long-term results on 3-5-year survival are available. In this review article data of the last 4 years on percutaneous RF ablation of HCC on cirrhosis are discussed in order to give an answer to questions put forward on this matter at 2000 EASL Barcelona Consensus Conference. Moreover, new perspectives in the percutaneous treatment of some form of advanced HCC (the so-called percutaneous thrombectomy) are presented together with some patents in the treatment of HCC.
Export Options
About this article
Cite this article as:
Giorgio Antonio, Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702226
DOI https://dx.doi.org/10.2174/157489210789702226 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Differences in Phosphorylated Histone H2AX Foci Formation and Removal of Cells Exposed to Low and High Linear Energy Transfer Radiation
Current Genomics Lessons from Viruses: Controlling the Function of Transmembrane Proteins by Interfering Transmembrane Helices
Current Medicinal Chemistry Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Regulation of HIPK Proteins by MicroRNAs
MicroRNA New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging The Ambidextrous Cyclooxygenase: An Enduring Target
Inflammation & Allergy - Drug Targets (Discontinued) Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design
Current Pharmaceutical Design PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery PET Tracers Based on 86Y
Current Radiopharmaceuticals Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib
Current Drug Targets Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
Current Pharmaceutical Design 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Recent Advances Into the Molecular Mechanisms and Therapeutic Targeting of Hepatocellular Carcinoma (Guest Editors: Dr. Mei-Sze Chua and Li Wang)]
Anti-Cancer Agents in Medicinal Chemistry Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design